Companies › Adverum Biotechnologies
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ixo-vec (ixoberogene soroparvovec) Intravitreal gene therapy expressing soluble fms-like tyrosine kinase-1 (sFlt-1), a VEGF t | FLT1 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Dec 2026 |
| ADVM-022 AAV gene therapy expressing aflibercept (VEGF inhibitor) | VEGFA | Phase 2 | Neovascular Age-related Macular Degeneration | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06856577 | Ixo-vec (ixoberogene soroparvovec) | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Dec 2026 |
| NCT07482176 | Ixo-vec (ixoberogene soroparvovec) | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Nov 2027 |
| NCT05536973 | ADVM-022 | Phase 2 | Neovascular Age-related Macular Degeneration | Ophthalmology | Aug 2028 |
| NCT07630649 | Ixo-vec (ixoberogene soroparvovec) | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Ophthalmology | Jun 2031 |
Innostellar Biotherapeutics jCyte MeiraGTx Ocular UK Tecnoquimicas NovaSight
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.